title: [cycEVA study: case control study measuring influenza vaccine effectiveness in Spain, 2008-2013].
abstract: BACKGROUND
  In Spain, influenza vaccine effectiveness (EV) is estimated since 2008-09 season through the cycEVA case-control study, the Spanish component of the European I-MOVE (Monitoring Influenza Vaccine Effectiveness in the EU/EEA) network. We aimed at describing cycEVA performance in its five consolidated editions 2008/09 -; 2012/13.
  
  
  METHODS
  During the study period the following indicators were analysed: 1) the participation of sentinel general practitioners and pediatricians (MP), 2) the population studied and the study period, 3) the data quality and 4) the dissemination of the cycEVA results. Trend analysis of the indicators was done using the Cochran-Armitage test to compute the Annual Percentage Change (PCA).
  
  
  RESULTS
  The number of participating MP increased from 164 in 2008-09 to 246 in the following editions. The percentage of MP recruiting at least one patient increased significantly annually (PCA = 15.33%). The percentage of recruited patients included into the analysis increased (PCA=5.91%) from 77% in 2008-09 to more than 95% in the following editions. The percentage of cycEVA patients contributing to the I-MOVE study ranged between 23% and 30% in the pilot and 2011-12 editions respectively.. Final results were disseminated in quartile 2 peer-reviewed journals and 2010-11 and 2011-12 preliminary EV estimates were published in quartile 1 journals. cycEVA publications received 97 citations.
  
  
  CONCLUSIONS
  cycEVA study achieved more quality information, timely EV estimates and a higher impact of the results.
authors.forename: Silvia
authors.initials: S
authors.lastname: Jiménez-Jorge
authors.forename: Salvador de
authors.initials: Sd
authors.lastname: Mateo Ontañón
authors.forename: Camelia
authors.initials: C
authors.lastname: Savulescu
authors.forename: Concepción
authors.initials: C
authors.lastname: Delgado-Sanz
authors.forename: Francisco
authors.initials: F
authors.lastname: Pozo Sánchez
authors.forename: Manuel
authors.initials: M
authors.lastname: García-Cenoz
authors.forename: Jesús
authors.initials: J
authors.lastname: Castilla Catalán
authors.forename: Carolina
authors.initials: C
authors.lastname: Rodríguez Gay
authors.forename: Tomás
authors.initials: T
authors.lastname: Vega Alonso
authors.forename: Carmen
authors.initials: C
authors.lastname: Quiñones Rubio
authors.forename: Eva
authors.initials: E
authors.lastname: Martínez Ochoa
authors.forename: Juana María
authors.initials: JM
authors.lastname: Vanrell Berga
authors.forename: Jaume
authors.initials: J
authors.lastname: Giménez Durán
authors.forename: Daniel
authors.initials: D
authors.lastname: Castrillejo Pérez
authors.forename: Jone Miren
authors.initials: JM
authors.lastname: Altzíbar Arotzena
authors.forename: Fernando
authors.initials: F
authors.lastname: González Carril
authors.forename: Julián Mauro
authors.initials: JM
authors.lastname: Ramos Aceitero
authors.forename: María del Carmen
authors.initials: Mdel C
authors.lastname: Serrano Martin
authors.forename: Ana
authors.initials: A
authors.lastname: Martínez i Mateo
authors.forename: Nuria
authors.initials: N
authors.lastname: Torner Gràcia
authors.forename: Esteban
authors.initials: E
authors.lastname: Pérez Morilla
authors.forename: Virtudes
authors.initials: V
authors.lastname: Gallardo García
authors.forename: Amparo
authors.initials: A
authors.lastname: Larrauri Cámara
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011643:Publishing; D012621:Seasons; D013030:Spain / Q000453:epidemiology
chemical_list: D007252:Influenza Vaccines